RecruitingPhase 2NCT06406465

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Studying Neuroendocrine neoplasm

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Jaydira Del Rivero, M.D.
National Cancer Institute (NCI)
Intervention
Belinostat(drug)
Enrollment
60 target
Eligibility
18-120 years · All sexes
Timeline
20262028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06406465 on ClinicalTrials.gov

Other trials for Neuroendocrine neoplasm

Additional recruiting or active studies for the same condition.

See all trials for Neuroendocrine neoplasm

← Back to all trials